Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Spotlight: Peripal, Easing Peritoneal Dialysis For ESRD

Executive Summary

Peritoneal dialysis (PD) can allow renal patients to dialyze at home, but connecting one’s catheter to the equipment carries an infection risk and is too tricky for some patients. Swiss startup Peripal AG, which closed a Series A1 round with prominent Swiss investors in July, is betting that its patient-aid device will make PD easier and safer while cutting costs for medical systems.

You may also be interested in...



COVID-19 Lessons: Experts Predict Shift Toward Intermittent Hemodialysis In ICUs

The pandemic may accelerate a move toward versatile, single-solution renal replacement therapy in intensive care.

Market Intel: Liquid Biopsies For Cancer Screening – Far From Reach Or Close At Hand?

While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target. Some question how practical such a test could be but several companies are already en route - some further down the road than others - to achieve this goal. Illumina spin-out Grail is one of these companies and while it is not alone, in a field where size matters, it may have an advantage. This article delves deeper into how these different technologies work and when they could reach the market.

Market Intel: Bioelectronics, Imaging Fortify Medtech's Defense Against Rheumatoid Arthritis

As rheumatoid arthritis treatment improves in the biologics era, patients need fewer joint replacements. Instead, they now require more closely monitored, agile care, in the face of a growing shortage of qualified rheumatologists. These demands help propel digital health applications, bioelectronic devices and novel imaging modalities into the medtech spotlight.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT121550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel